Abstract
Between July 2001 and June 2007, 48 consecutive patients with β-thalassaemia major received allogeneic haematopoietic stem cell transplants (allo HSCT) from human-leukocyte-antigen-matched siblings at the Armed Forces Bone Marrow Transplant Centre, Rawalpindi, Pakistan, using standard conditioning regimens. The median age of the patient cohort was 4 years (range, 1–14 years). Thirty-one patients were in risk class I, 11 in class II and six patients were in class III. Engraftment was achieved in all patients. Survival was calculated from the date of transplant to death or last follow-up. Major post-transplant complications encountered were acute graft versus host disease (Ac GvHD) (grades II–IV), 35.4%; chronic GvHD, 8.3%; haemorrhagic cystitis, 12.5%; veno-occlusive disease (VOD) of the liver, 6.2%; bacterial infections, 37.5%; fungal infections, 19%; cytomegalovirus (CMV) infection, 6.2%; herpes infection, 6.2%; and tuberculosis in 2% of patients. Graft rejection was observed in five patients. Three patients received second transplants. Mortality was observed in 20.8% of patients. Major fatal complications included GvHD, VOD, intracranial haemorrhage, septicaema, CMV disease and disseminated tuberculosis. Overall survival and disease-free survival were 79% and 75%, respectively, at 6 years post-HSCT.
Similar content being viewed by others
References
Weatherall, Clegg JG (1981) The thalassemia syndromes. Blackwell, Oxford, pp 744–782
Lucarelli G, Giardini C (1995) Bone marrow transplantation in B-thalassaemia major: a survey of 13 year activity of a single institure. Forum 5.5:472–484
Ahmed S, Patrou M, Saleem M (1997) Molecular genetics of B-thalassaemia in Pakistan: a basis for prenatal diagnosis. Br J Haematol 97:504
Giardini C, Galimberti M, Lucarelli G (1995) Bone marrow transplantation in thalassemia. Annu Rev Med 46:319–330
Bader P, Niethammer D, Willasch A, Kreyenberg H, Klingebiel T (2005) How and when should we monitor chimerism after allogeneic stem cell transplantation. Bone Marrow Transplant 35:107–119
Gratwohl A, Baldomero H, Frauendorfer K, Urbano-Ispizua A, Niederwieser D, for the Joint Accreditation Committee of the International Society for Cellular Therapy ISCT and the European Group for Blood and Marrow Transplantation EBMT (JACIE) (2007) Results of the EBMT activity survey 2005 on haematopoietic stem cell transplantation: focus on increasing use of unrelated donors. Bone Marrow Transplant 39:71–87
Sevilla J, Fernandez-Plaza S, Diaz MA, Madero L (2005) Hematopoietic transplantation for bone marrow failure syndromes and thalassemia. Bone Marrow Transplant 35:S17–S21
Rizvi SAH, Naqvi SAA, Hussain Z, Hashmi A, Akhtar F, Hussain M et al (2002) Emerging challenges in transplantation in developing countries. Transplant Proc. 2002:3146–3149 Elsevier, Amsterdam
Lucarelli G, Andreani M, Angelucci E (2002) The cure of thalassemia by bone marrow transplantation. Blood Rev 16:81–85
Glucksberg H, Strob R, Fefer A, Buckner CD, Neiman PE, Clift RA et al (1974) Clinical manifestations of graft-versus-host disease in human recipients of marrow from HLA matched sibling donors. Transplantation 18:295–304
Ullah K, Shamsi TS, Adil SN. Bone marrow transplant activity in developing world, A country report from Pakistan of the APBMT Proceedings 11th congress Oct 27–29, 2006, Nagoya, Japan
Chandy M, Srivastava A, Dennison D, Mathews V, George B (2001) Allogeneic bone marrow transplantation in the developing world: experience from a center in India. Bone Marrow Transplant 27:785–790
Ramzi M, Noorani H, Zakernia M, Haghshenas M (2004) Allogeneic stem cell transplantation experience in southern Iran. Bone Marrow Transplant 33:R–1228
Lazarus HM, Vogelsang GB, Row JM (1997) Prevention and treatment of acute graft versus host disease the old and the new. A report from the Eastern Cooperative Oncology Group (ECOG). Bone Marrow Transplant 3(19):577–600
Atkinson K (1990) Chronic graft versus host disease. Bone Marrow Transplant 5:69–82
Kondo M, Kojima S, Horibe K, Kato K, Matsuyama T (2001) Risk factors for chronic graft versus host disease after allogeneic stem cell transplantation in children. Bone Marrow Transplant 27(727):30
Ghavamzadeh A, Jahani M, Mousavi A, Bahar B, Iravani M, Alimoghaddam K (2004) Chronic GvHD outcome in thalassaemia major patients (12 year experience in Iran). Bone Marrow Transplant 33:P625
Locatelli F, Uderzo C, Dini G (1993) Graft-versus-host disease in children: the AIEOP-BMT Group experience with cyclosporin A. Bone Marrow Transplant 12:627–633
Lucarelli G, Andreani M, Angelucci E (2001) The cure of the thalassemia with bone marrow transplantation. Bone marrow transplant 28(Suppl. 1):S11–S13
Hayes-Lattin B, Leis JF, Maziarz RT (2005) Isolation in the allogeneic transplant environment: how protective is it. Bone Marrow Transplant 36:373–381
Fujimaki K, Maruta A, Yoshida M, Kodama F, Matsuzaki M, Fujisawa S et al (2001) Immune reconstitution assessed during five years after allogeneic bone marrow transplantation. Bone Marrow Transplant 27:1275–1281
Collin BA, Leather HL, Wingard JR, Ramphal R (2001) Evolution, incidence and susceptibility of bacterial bloodstream isolates from 519 bone marrow transplant patients. Clin Infect Dis 33:947–953
Wang CC, Mattson D, Wald A (2001) Corynebacterium jeikeium bacteremia in bone marrow transplant patients with Hickman catheters. Bone Marrow Transplant 27:445–449
Ghosh K, Shenoy AK, Al-Mahrooqi Z (2002) Bacteriological infections during the first hundred days of allogeneic bone marrow transplantation—experience from Oman. J Assoc Physicians India 50:910–912
Arns da Cunba C, Weisdorf D, Shu XO, Defor T, Pastor JD III, Johnson JR (1998) Early gram positive bacteremia in BMT recipients: impact of three different approaches to antimicrobial prophylaxis. Bone Marrow Transplant 21:173–180
George B, Mathews V, Viswabandya A, Srivastava A, Chandy M (2006) Infections in children undergoing allogeneic bone marrow transplantation in India. Pediatr transplant 10:48–54
Kindler T, Schindel C, Brass U, Fischer T (2001) Fatal sepsis due to Mycobacterium tuberculosis after allogeneic bone marrow transplantation. Bone Marrow Transplant 27:217–218
Lee J, Lee MH, Kim WS, Kim K, Park SH, Lee SH et al (2004) Tuberculosis in hematopoietic stem cell transplant recipients in Korea. Int J Hematol 79:185–188
Arslan O, Gurman G, Dilek I, Ozcan M, Koc H, Ilhan O et al (1998) Incidence of tuberculosis after bone marrow transplantation in a single centre from Turkey. Haematologia 29:59–62
Ku S-C, Tang J-L, Hsueh P-R, Luh KT, Yu CJ, Yang PC (2001) Pulmonary tuberculosis in allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 27:1293–1297
George B, Mathews V, Srivastava V, Srivastave A, Chandy M (2001) Tuberculosis among allogeneic bone marrow transplant recipients in India. Bone Marrow Transplant 27:973–975
Marr KA, Seidel K, Slavin MA, Bowden RA, Schoch HG, Flowers ME et al (2000) Prolonged fluconazole prophylaxis is associated with persistent protection against candidiasis-related death in allogeneic marrow transplant recipients: long term follow-up of a randomized, placebo-controlled trial. Blood 96:2055–2061
Safdar A, Van Rhee F, Henslee-Downey JP, Singhal S, Mehta J (2001) Candida glabrata and Candida krusei fungemia after high-risk allogenic marrow transplantation: no adverse effect of low-dose fluconazole prophylaxis on incidence and outcome. Bone Marrow Transplant 28:873–878
Weinberger M, Sacks T, Sulkes J, Shapiro M, Polacheck I (1997) Increasing fungal isolation from clinical specimens: experience in a university hospital over a decade. J Hosp Infect 35:185–195
George B, Mathew V, Srivastava A, Chandy M (2004) Infections among allogeneic bone marrow transplant recipients in India. Bone Marrow Transplant 33:311–315
Wingard JR, Piantadosi S, Burns WH, Zahurak ML, Santos GW, Saral R (1990) Cytomegalovirus infections in patients treated by intensive cytoreductive therapy with marrow transplant. Clin Infect Dis 12(Suppl.7):S793–S804
Wingard JR (1990) Advances in the management of infectious complications after bone marrow transplantation. Bone Marrow Transplant 6:371–383
Reusser P, Einsele H, Lee J, Volin L, Rovira M, Engelhard D et al (2002) Randomized multicentre trial of foscarnet versus ganciclovir for pre-emptive therapy of cytomegalovirus infection after allogeneic stem cell transplantation. Blood 99:1159–1164
Ljungman P, Deliliers GL, Plaztzbecker U, Matthes-Martin S, Bacigalupo A, Einsele H et al (2001) Cidofovir for cytomegalovirus infection and disease in allogeneic stem cell transplant recipients. The infectious diseases working party of the European group for blood and marrow transplantation. Blood 97:388–392
Sodani P, Gaziev D, Polchi P (2004) New approach for bone marrow transplantation in class 3 thalassaemic patients aged less than 17 years. Blood 104:1201–1203
Lawson SE, Roberts IAG, Amrolia P, Dokal I, Szydlo R, Darbyshire PJ (2003) Bone Marrow Transplant for b-thalassaemia major. Br J Haematol 120:289
Yesilipek MA, Hazar V, Kupesiz A, Kuzilors A, Uguz A, Yegin O (2001) Peripheral blood stem cell transplantation in children with beta-thalassemia. Bone Marrow Transplant 28:1037–1040
Acknowledgment
We thank the Departments of Microbiology, Virology and Molecular Biology of the Armed Forces Institute of Pathology, Rawalpindi, Pakistan, for helpful contributions, technical assistance and discussions. We also thank the Armed Forces Institute of Transfusion, Rawalpindi, Pakistan, for generously providing us with blood products. We are extremely grateful to Mr. Haroon Rafique of this centre for helping us in statistical analysis and manuscript preparation.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Ullah, K., Khan, B., Raza, S. et al. Bone marrow transplant cure for β-thalassaemia major: initial experience from a developing country. Ann Hematol 87, 655–661 (2008). https://doi.org/10.1007/s00277-008-0478-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00277-008-0478-8